Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 29-37

  Vidal, Liat ^a   Paul, Mical ^a,b   Ben dor, Itsik ^a   Soares Weiser, Karla ^a   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antimicrobial drugs; Fever; Neutropenic patients

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZLOCILLIN; AZTREONAM; CARBENICILLIN; CEFIXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; GENTAMICIN; OFLOXACIN; PENICILLIN V; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TOBRAMYCIN;

BIBLIOGRAPHIC DATABASE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; DRUG EFFICACY; EMBASE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; MEDLINE; META ANALYSIS; METHODOLOGY; MORTALITY; NEUTROPENIA; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER; HUMANS; INJECTIONS, INTRAVENOUS; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 3543092094     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh303     Document Type: Review

References (65)

1. Bodey, G. P. (1966). Infectious complications of acute leukemia. Medical Times 94, 1076-85.
2. Bodey, G. P., Buckley, M., Sathe, Y. S. et al. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64, 328-40.
3. Pizzo, P. A., Robichaud, K. J., Wesley, R. et al. (1982). Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 61, 153-65.
4. Schimpff, S. C. (1986). Empiric antibiotic therapy for granulocytopenic cancer patients. American Journal of Medicine 80, 13-20.
5. Hughes, W. T., Armstrong, D., Bodey, G. P. et al. (2002). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Disease 34, 730-51.
6. Talcott, J. A., Finberg, R., Mayer, R. J. et al. (1988). The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Archives of Internal Medicine 148, 2561-8.
7. Klaassen, R. J., Goodman, T. R., Pham, B. et al. (2000). "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology 18, 1012-9.
8. Klastersky, J., Paesmans, M., Rubenstein, E. B. et al. (2000). The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 18, 3038-51.
9. Talcott, J. A., Siegel, R. D., Finberg, R. et al. (1992). Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology 10, 316-22.
10. Malik, I. A., Abbas, Z. & Karim, M. (1992). Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339, 1092-6.
11. Rubenstein, E. B., Rolston, K., Benjamin, R. S. et al. (1993). Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71, 3640-6.
12. From the Immunocompromised Host Society (1990). The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Disease 161, 397-401.
13. Feld, R. (1998). Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Supportive Care in Cancer 6, 444-8.
14. Clarke, M. & Oxman, A., eds. (2003) Cochrane Reviewers, Handbook 4.2.0 (updated March 2003) [Online.] http://www.cochrane.dk/cochrane/handbook/handbook.htm (30 April 2003, date last accessed)
15. Schulz, K. F., Chalmers, I., Hayes, R. J. et al. (1995). Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 273, 408-12.
16. Begg, C. B. & Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-101.
17. Cornelissen, J. J., Rozenberg-Arska, M. & Dekker, A. W. (1995). Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clinical Infectious Disease 21, 1300-2.
18. Aquino, V. M., Herrera, L., Sandler, E. S. et al. (2000). Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenic. In selected children with cancer. Cancer 88, 1710-4.
19. Bash, R. O., Katz, J. A., Cash, J. V. et al. (1994). Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74, 189-96.
20. Gardembas-Pain, M., Desablens, B., Sensebe, L. et al. (1991). Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Annals of Oncology 2, 485-7.
21. Lau, R. C., Doyle, J. J., Freedman, M. H. et al. (1994). Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Journal of Pediatrics Hematology/Oncology 11, 417-21.
22. Horowitz, H. W., Holmgren, D. & Seiter, K. (1996). Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leukemia and Lymphoma 23, 159-63.
23. Malik, I. A., Khan, W. A., Aziz, Z. et al. (1994). Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Disease 19, 522-7.
24. Malik, I. A. (1997). Out-patient management of febrile neutropenia in indigent paediatric patients. Annals of the Academy of Medicine Singapore (Singapore) 26, 742-6.
25. Marra, C. A., Frighetto, L., Quaia, C. B. et al. (2000). A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 20, 931-40.
26. Mustafa, M. M., Aquino, V. M., Pappo, A. et al. (1996). A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics 128, 847-9.
27. Berrahal, F., Baume, D., Burley, S. et al. (1996). A study of intravenous ticarcillin/clavulanic acid and oral ciprofloxacin in the treatment of febrile neutropenic patients. [French]. Journal de Pharmacie Clinique 15, 74-7.
28. Paganini, H. R., Rodriguez Brieshcke, T. & Zubizarreta, P. (2001). [Criteria of low risk of mortality in children with neutropenia and fever during cancer chemotherapy]. Medicina (B Aires) 61, 63-6.
29. Papadimitris, C., Dimopoulos, M. A., Kostis, E. et al. (1999). Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology 57, 127-30.
30. Vallejo, C., Caballero, M. D. & Garcia-Sanz, R. (1997). Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology & Cell Therapy 39, 223-7.
31. Wacker, P., Halperin, D. S., Wyss, M. et al. (1997). Early hospital discharge of children with fever and neutropenia: a prospective study. Journal of Pediatrics Hematology/Oncology 19, 208-11.
32. Aquino, V. M., Buchanan, G. R., Tkaczewski, I. et al. (1997). Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Medical and Pediatric Oncology 28, 191-5.
33. Freifeld, A. & Pizzo, P. (1997). Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatric Infectious Disease Journal 16, 140-5; discussion 145-6, 160-142.
34. Mullen, C. A. (2001). Which children with fever and neutropenia can be safely treated as outpatients? British Journal of Haematology 112, 832-7.
35. Montalar Salcedo, J., Oltra Ferrando, A., Segura Huerta, A. et al. (1999). Ofloxacin as monotherapy in the treatment of neutropenic fever. Oncologia 22, 42-7.
36. Nepokul'chitskaia, N. V., Timakov, A. M., Kondratchik, K. L. et al. (1998). [Cephalosporins in the treatment of children with oncohematologic diseases]. Antibiotiki i Khimioterapiia (Moskva) 43, 30-2.
37. Santolaya, M. E., Villarroel, M., Avendano, L. F. et al. (1997). Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clinical Infectious Disease 25, 92-7.
38. Klaassen, R. J., Allen, U. & Doyle, J. J. (2000). Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. Journal of Pediatrics Hematology/Oncology 22, 405-11.
39. Paganini, H., Rodriguez-Brieshcke, T., Zubizarreta, P. et al. (2001). Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 91, 1563-7.
40. Rapoport, B. L., Sussmann, O., Herrera, M. V. et al. (1999). Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care. Chemotherapy 45, 466-76.
41. Meunier, F., Zinner, S. H., Gaya, H. et al. (1991). Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrobial Agents and Chemotherapy 35, 873-8.
42. Malik, I. A., Khan, W. A., Karim, M. et al. (1995). Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. American Journal of Medicine 98, 224-31.
43. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1994). Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. Journal of the American Medical Association 272, 1183-9.
44. Kibbler, C. C., Pomroy, L., Sage, R. J. et al. (1987). The use of ciprofloxacin in the treatment of febrile neutropenic patients. In Proceedings of the Thirty-third European Congress of Clinical Microbiology, The Hague, Netherlands, 1987. Abstract 357
45. Mullen, C. A., Petropoulos, D., Roberts, W. M. et al. (1999). Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. Journal of Pediatrics Hematology/Oncology 21, 212-8.
46. Minotti, V., Gentile, G., Bucaneve, G. et al. (1999). Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer 7, 134-9.
47. Flaherty, J. P., Waitley, D., Edlin, B. et al. (1989). Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. American Journal of Medicine 87, 278S-82S.
48. Freifeld, A., Marchigiani, D., Walsh, T. et al. (1999). A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine 341, 305-11.
49. Giamarellou, H., Bassaris, H. P., Petrikkos, G. et al. (2000). Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrobial Agents and Chemotherapy 44, 3264-71.
50. Hidalgo, M., Hornedo, J., Lumbreras, C. et al. (1999). Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85, 213-9.
51. Kern, W. V., Cometta, A., De Bock, R. et al. (1999). Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine 341, 312-8.
52. Mullen, C. A., Petropoulos, D., Roberts, W. M. et al. (1999). Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86, 126-34.
53. Paganini, H. R., Sarkis, C.M., De Martino, M. G. et al. (2000). Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 88, 2848-52.
54. Petrilli, A. S., Dantas, L. S., Campos, M. C. et al. (2000). Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology 34, 87-91.
55. Shenep, J. L., Flynn, P. M., Baker, D. K. et al. (2001). Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clinical Infectious Disease 32, 36-43.
56. Velasco, E., Costa, M. A., Martins, C. A. et al. (1995). Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. American Journal of Clinical Oncology - Cancer Clinical Trials 18, 429-35.
57. Innes, H. E., Smith, D. B., O'Reilly, S. M. et al. (2003). Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer 89, 43-9.
58. Rolston, K., Rubenstein, E., Elting, L., et al. (1995). Ambulatory management of febrile episodes in low-risk neutropenic patients. In Programs and Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract LM81. American Society for Microbiology, Washington, DC, USA.
59. Samonis, G., Anaissie, E. J., Kalbakis, K., et al. (1997). Therapy for low-risk cancer patients with fever and neutropenia: results of a prospective, randomized trial with cost analysis. In Programs and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1997. Abstract LM51. American Society for Microbiology, Washington, DC, USA.
60. Lucas, K. G., Brown, A. E., Armstrong, D. et al. (1996). The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77, 791-8.
61. Rackoff, W. R., Gonin, R., Robinson, C. et al. (1996). Predicting the risk of bacteremia in childen with fever and neutropenia. Journal of Clinical Oncology 14, 919-24.
62. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1990). Gram-positive bacteraemia in granulocytopenic cancer patients. European Journal of Cancer 26, 569-74.
63. Jones, B., Jarvis, P., Lewis, J. A. et al. (1996). Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 313, 36-9.
64. Feld, R. (2000). Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal of Antimicrobial Agents 16, 185-7.
65. Feld, R., Paesmans, M., Freifeld, A. G. et al. (2002). Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical Infectious Disease 35, 1463-8.